



COPY OF PAPERS  
ORIGINALLY FILED

Due Date: September 2, 2002

1646  
RECEIVED

SEP 06 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark E. Johnson et al.	Examiner:	To Be Assigned
Serial No.:	10 054,488	Group Art Unit:	1646
Filed:	January 22, 2002	Docket:	G&C 126.4-US-U1
Title:	MICROSPHERE DELIVERY OF MUCIN PEPTIDES		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 29, 2002

By: 

Name: Karen S. Canady

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Information Disclosure Statement and Form PTO-1449.
- ☒ Cited Reference(s).
- ☒ Return postcard.

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.

Please charge any additional fees or credit any overpayment to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

Customer Number 22462

**GATES & COOPER LLP**

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, CA 90045  
(310) 641-8797

By: 

Name: Karen S. Canady

Reg. No.: 39,927

KSC/kmf

(PTO TRANSMITTAL - GENERAL)



OF PATENTS  
ORIGINALLY FILED

RECEIVED

SEP 06 2002


TECH CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark E. Johnson et al.	Examiner:	To Be Assigned
Serial No.:	10/054,488	Group Art Unit:	1646
Filed:	January 22, 2002	Docket:	G&C 126.4-US-U1
Title:	MICROSPHERE DELIVERY OF MUCIN PEPTIDES		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 29, 2002.

By:   
Name: Karen S. Canady

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as

being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.


Respectfully submitted,


GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: August 29, 2002

KSC/kmf

By:   
\_\_\_\_\_  
Karen S. Canady  
Reg. No.: 39,927



Form 1449*	Docket Number: G&C 126 4-US-U1	Application Number: 10/054,488
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		
Applicant: Mark E. Johnson et al		
Filing Date: January 22, 2002	Group Art Unit: 1646	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,407,609	04-18-95	Fice et al.			
	5,744,144	04-28-98	Finn et al.			
	5,827,666	10-27-98	Finn et al.			

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

SEP 06 2002

TECH CENTER 1600/2900

## FOREIGN PATENTS

	DOCUMENT NO	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS Including Author, Title, Date, Pertinent Pages, Etc

	S.M. Barratt-Boyes, et al., "Immunization of Chimpanzees with Tumor Antigen MUC1 Mucin Tandem Repeat Peptide Elicits Both Helper and Cytotoxic T-Cell Responses," Clinical Cancer Research, 1999, 5: 1918 - 1924.
	S. Cohen et al., "Controlled Delivery Systems for Proteins Based on Poly Lactic, Glycolic Acid, Microspheres," Pharmaceutical Research, 1991, 8 6: 713 - 720.
	J.H. Eldridge et al., "Biodegradable Microspheres as a Vaccine Delivery System," Molecular Immunology, 1991, 28 3: 287 - 294.
	J.D. Fontenot et al., "Biophysical Characterization of One-, Two-, and Three-Tandem Repeats of Human Mucin-muc-1 Protein Core," Cancer Research, 1993, 53: 5386 - 5394.
	D.A. Johnson et al., "3-O-Desacyl Monophosphoryl Lipid A Derivatives: Synthesis and Immunostimulant Activities," J. Med. Chem., 1999, 42: 4640 - 4649.
	Y. Kotera et al., "Humoral Immunity Against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients," Cancer Research, 1994, 54: 2856 - 2860.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.